Arzerra (ofatumumab) Intravenous — Medical Necessity and Utilization Management Criteria
Medical necessity and utilization management criteria for intravenous ofatumumab (Arzerra) covering indications, dosing limits, authorization length, and renewal requirements for EmblemHealth members.
Updated dosing limits and removed stage-based requirement for CLL; clarified indications including combination with fludarabine and cyclophosphamide for relapsed CLL and extended treatment after at least two lines of therapy.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.